Investors who own more than 5% of a class must file a Schedule 13D or 13G. Every filing for 747324101 since 12/18/2024, newest first.
| Filer | % of Class | Filed | |
|---|---|---|---|
|
GordonMD Global Investments LP
13G/A
Amendment 3
|
16.4% |
10/9/2026
Event 10/1/2026
|
|
| GordonMD Global Investments LP | 16.4% | ||
| GordonMD Long Biased Master Fund LP | 16.4% | ||
| GordonMD Long Biased GP LLC | 16.4% | ||
| Craig D. Gordon | 16.4% | ||
|
Coastlands Capital LP
13G
|
5.4% |
10/5/2026
Event 10/1/2026
|
|
| Coastlands Capital LP | 5.4% | ||
| Coastlands Capital Partners LP | 5.4% | ||
| Coastlands Capital GP LLC | 5.4% | ||
| Coastlands Capital LLC | 5.4% | ||
| Matthew D. Perry | 5.4% | ||
|
GordonMD Global Investments LP
13G/A
Amendment 2
|
17.5% |
10/2/2026
Event 10/1/2026
|
|
| GordonMD Global Investments LP | 17.5% | ||
| GordonMD Long Biased Master Fund LP | 17.5% | ||
| GordonMD Long Biased GP LLC | 17.5% | ||
| Craig D. Gordon | 17.5% | ||
|
Biotechnology Value Fund L P
13G
|
10.0% |
7/10/2026
Event 7/2/2026
|
|
| Biotechnology Value Fund L P | 5.5% | ||
| BVF I GP LLC | 5.5% | ||
| Biotechnology Value Fund II LP | 3.7% | ||
| BVF II GP LLC | 3.7% | ||
| Biotechnology Value Trading Fund OS LP | 0.6% | ||
| BVF Partners OS Ltd. | 0.6% | ||
| BVF GP Holdings LLC | 9.2% | ||
| BVF Partners L P/IL | 10.0% | ||
| BVF Inc/IL | 10.0% | ||
| Lampert Mark N | 10.0% | ||
|
GordonMD Global Investments LP
13G/A
Amendment 1
|
12.1% |
7/2/2026
Event 6/30/2026
|
|
| GordonMD Global Investments LP | 12.1% | ||
| GordonMD Long Biased Master Fund LP | 12.1% | ||
| GordonMD Long Biased GP LLC | 12.1% | ||
| Craig D. Gordon | 12.1% | ||
|
Laurion Capital Management LP
13G/A
Amendment 2
|
7.7% |
2/9/2026
Event 12/31/2025
|
|
| Laurion Capital Management LP | 7.7% | ||
| Benjamin Alexander Smith | 7.7% | ||
| Janaka Sheehan Maduraperuma | 7.7% | ||
|
Millennium Management LLC
13G/A
Amendment 1
|
1.3% |
10/14/2025
Event 9/30/2025
|
|
| Millennium Management LLC | 1.3% | ||
| Millennium Group Management LLC | 1.3% | ||
| Israel A. Englander | 1.3% | ||
|
GordonMD Global Investments LP
13G
|
6.2% |
9/23/2025
Event 7/14/2025
|
|
| GordonMD Global Investments LP | 6.2% | ||
| GordonMD Long Biased Master Fund LP | 6.2% | ||
| GordonMD Long Biased GP LLC | 6.2% | ||
| Craig D. Gordon | 6.2% | ||
| BlackRock, Inc. 13G/A Amendment 1 | 1.5% |
7/17/2025
Event 6/30/2025
|
|
|
Millennium Management LLC
13G
|
5.7% |
7/1/2025
Event 6/27/2025
|
|
| Millennium Management LLC | 5.7% | ||
| Millennium Group Management LLC | 5.7% | ||
| Israel A. Englander | 5.7% | ||
|
Integrated Core Strategies (US) LLC
13G/A
Amendment 1
|
4.0% |
5/6/2025
Event 3/31/2025
|
|
| Integrated Core Strategies (US) LLC | 4.0% | ||
| Millennium Management LLC | 4.0% | ||
| Millennium Group Management LLC | 4.0% | ||
| Israel A. Englander | 4.0% | ||
| Sullivan Lara 13D/A Amendment 5 | 11.2% |
4/2/2025
Event 3/31/2025
|
|
|
Deep Track Capital, LP
13G/A
Amendment 1
|
0% |
2/14/2025
Event 12/31/2024
|
|
| Deep Track Capital, LP | 0% | ||
| Deep Track Biotechnology Master Fund, Ltd. | 0% | ||
| David Kroin | 0% | ||
|
Ridgeback Capital Investments L.P.
13G/A
Amendment 1
|
0.6% |
2/14/2025
Event 12/31/2024
|
|
| Ridgeback Capital Investments L.P. | 0.6% | ||
| Ridgeback Capital Investments LLC | 0.6% | ||
| Ridgeback Capital Management LLC | 0.6% | ||
| BlackRock, Inc. 13G | 5.6% |
2/4/2025
Event 12/31/2024
|
|
| Lara Sullivan 13D/A Amendment 4 | 10.3% |
12/23/2024
Event 12/23/2024
|
|
|
Integrated Core Strategies (US) LLC
13G
|
5.3% |
12/16/2024
Event 12/9/2024
|
|
| Integrated Core Strategies (US) LLC | 5.3% | ||
| Millennium Management LLC | 5.3% | ||
| Millennium Group Management LLC | 5.3% | ||
| Israel A. Englander | 5.3% |
| Period | Filings | Shares, Excl. Options | Value, Excl. Options |
|---|---|---|---|
| 2026 Q2 | 82 | 34.2 M | $101 M |
| 2026 Q1 | 81 | 27.6 M | $40.5 M |
| 2025 Q4 | 82 | 30.2 M | $34.7 M |
| 2025 Q3 | 75 | 26.8 M | $59.8 M |
| 2025 Q2 | 76 | 27.5 M | $30.3 M |
| 2025 Q1 | 94 | 30.3 M | $29.7 M |
| 2024 Q4 | 104 | 31.6 M | $49.2 M |
| 2024 Q3 | 102 | 27.9 M | $103 M |
| 2024 Q2 | 88 | 28.2 M | $93.4 M |
| 2024 Q1 | 80 | 23.0 M | $98.0 M |
| 2023 Q4 | 57 | 8.80 M | $15.8 M |
| 2023 Q3 | 56 | 7.81 M | $15.4 M |
| 2023 Q2 | 50 | 9.61 M | $24.6 M |
| 2023 Q1 | 48 | 10.4 M | $41.5 M |
| 2022 Q4 | 33 | 19.8 M | $26.6 M |
| 2022 Q3 | 39 | 19.4 M | $38.3 M |
| 2022 Q2 | 40 | 20.0 M | $47.7 M |
| 2022 Q1 | 46 | 18.9 M | $76.1 M |
| 2021 Q4 | 53 | 20.3 M | $221 M |